secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001867096-23-000110
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Q2 revenue $38.0M record, up 50% YoY; tightens FY23 guidance upward
-------------------------------------------------------------------------

- Record total revenue $38.0M, QoQ +14%, YoY +50%; product revenue $36.9M (+46%).
- Gvoke net revenue $15.6M (+36%), Keveyis $14.1M (+10%), Recorlev $7.2M.
- FY23 revenue guidance tightened to $145M-165M from $135M-165M; cash utilization reduced to $57M-67M.
- Cash, equivalents and short-term investments $80.7M at June 30; on track for cash flow breakeven by year-end.
- Net loss $19.8M ($0.14 per share); Phase 2 study of XP-8121 (levothyroxine) began dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/0001867096-23-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/xers-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer